NO995482D0 - Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister - Google Patents

Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister

Info

Publication number
NO995482D0
NO995482D0 NO995482A NO995482A NO995482D0 NO 995482 D0 NO995482 D0 NO 995482D0 NO 995482 A NO995482 A NO 995482A NO 995482 A NO995482 A NO 995482A NO 995482 D0 NO995482 D0 NO 995482D0
Authority
NO
Norway
Prior art keywords
receptor antagonists
somatostatin receptor
ergoline derivatives
ergoline
derivatives
Prior art date
Application number
NO995482A
Other languages
English (en)
Norwegian (no)
Other versions
NO995482L (no
Inventor
Paul Pfaeffli
Peter Neumann
Robert Swoboda
Peter Stuetz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO995482L publication Critical patent/NO995482L/no
Publication of NO995482D0 publication Critical patent/NO995482D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO995482A 1997-05-29 1999-11-09 Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister NO995482D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711043.1A GB9711043D0 (en) 1997-05-29 1997-05-29 Organic compounds
PCT/EP1998/003125 WO1998054183A2 (en) 1997-05-29 1998-05-27 Ergoline derivatives and their use as somatostatin receptor antagonists

Publications (2)

Publication Number Publication Date
NO995482L NO995482L (no) 1999-11-09
NO995482D0 true NO995482D0 (no) 1999-11-09

Family

ID=10813201

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995482A NO995482D0 (no) 1997-05-29 1999-11-09 Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister

Country Status (24)

Country Link
US (1) US6221870B1 (tr)
EP (1) EP0986558A2 (tr)
JP (1) JP2001527580A (tr)
KR (1) KR20010013103A (tr)
CN (1) CN1259946A (tr)
AR (1) AR012870A1 (tr)
AU (1) AU727841B2 (tr)
BR (1) BR9809491A (tr)
CA (1) CA2288810A1 (tr)
CO (1) CO4950561A1 (tr)
CZ (1) CZ289466B6 (tr)
GB (1) GB9711043D0 (tr)
HU (1) HUP0002311A3 (tr)
ID (1) ID22916A (tr)
IL (1) IL132571A0 (tr)
NO (1) NO995482D0 (tr)
NZ (1) NZ500386A (tr)
PE (1) PE74899A1 (tr)
PL (1) PL336502A1 (tr)
RU (1) RU2191776C2 (tr)
SK (1) SK160899A3 (tr)
TR (1) TR199902848T2 (tr)
WO (1) WO1998054183A2 (tr)
ZA (1) ZA984560B (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10341317B4 (de) * 2003-09-03 2008-10-23 Axxonis Pharma Ag Transdermales therapeutisches System (TTS) zur Verabreichung von Ergolinverbindungen ausgenommen Pergolid
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
PT2062914E (pt) * 2001-06-08 2014-07-18 Ipsen Pharma Sas Análogos quiméricos de somatostatina-dopamina
FI20031454A0 (fi) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
KR101000923B1 (ko) * 2004-01-08 2010-12-13 삼성전자주식회사 원격 제어기의 매크로 설정 장치 및 방법
US20100048549A1 (en) * 2005-05-18 2010-02-25 Siegfried Wurster Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
JP2007067096A (ja) * 2005-08-30 2007-03-15 Fujitsu Ltd 半導体装置
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
EP2793583A4 (en) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc NOVEL NEUROMODULATORY CONNECTIONS
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
JP2016503402A (ja) 2012-11-01 2016-02-04 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． ソマトスタチン類似体及びそのダイマー
CN107428745A (zh) 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
JP7099717B2 (ja) 2019-09-30 2022-07-12 株式会社理研バイオ ソマトスタチン受容体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH475252A (de) * 1966-02-08 1969-07-15 Sandoz Ag Verfahren zur Herstellung neuer Lysergsäure-Derivate
US3592816A (en) 1966-02-08 1971-07-13 Sandoz Ltd N-substituted piperazides of lysergic acid
GB1188197A (en) 1967-10-11 1970-04-15 Sandoz Ltd Lysergic Acid Derivatives
NL6818658A (tr) * 1968-01-18 1969-07-22
GB1580448A (en) * 1976-12-06 1980-12-03 Farmaceutici Italia 8 -acetyl-6-methyl-ergoline i derivatives
GB8501078D0 (en) * 1985-01-16 1985-02-20 Erba Farmitalia Piperazin-1-yl-ergo-line derivatives
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives

Also Published As

Publication number Publication date
PL336502A1 (en) 2000-07-03
ID22916A (id) 1999-12-16
NZ500386A (en) 2002-05-31
ZA984560B (en) 1998-11-30
CA2288810A1 (en) 1998-12-03
PE74899A1 (es) 1999-09-14
US6221870B1 (en) 2001-04-24
GB9711043D0 (en) 1997-07-23
HUP0002311A3 (en) 2002-08-28
AU727841B2 (en) 2001-01-04
BR9809491A (pt) 2000-10-17
CZ289466B6 (cs) 2002-01-16
WO1998054183A2 (en) 1998-12-03
EP0986558A2 (en) 2000-03-22
NO995482L (no) 1999-11-09
IL132571A0 (en) 2001-03-19
JP2001527580A (ja) 2001-12-25
AR012870A1 (es) 2000-11-22
HUP0002311A2 (hu) 2000-12-28
CO4950561A1 (es) 2000-09-01
TR199902848T2 (tr) 2000-02-21
SK160899A3 (en) 2000-07-11
CN1259946A (zh) 2000-07-12
CZ424599A3 (cs) 2000-03-15
WO1998054183A3 (en) 1999-03-04
RU2191776C2 (ru) 2002-10-27
KR20010013103A (ko) 2001-02-26
AU8210898A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
NO995482D0 (no) Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister
DK1394150T3 (da) 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
NO985225L (no) Indolderivater nyttige som endotelinreseptorantagonister
DK1086086T3 (da) Imidazolylderivater og anvendelse deraf som somatostatinreceptorligander
NO20000108L (no) Sulfonamid-derivater som er 5-HT6-reseptorantagonister og fremgangsmÕte for deres fremstilling
DK1157005T3 (da) 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
IS5706A (is) Adenosín A3 viðtakastillar
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
DE69734833D1 (de) Vitronektin rezeptor antagonisten
DE69833073D1 (de) CCR-3-Rezeptor-Antagonisten
DK0880523T3 (da) Pyrazolopyrimidiner som CRF-receptorantagonister
NO20020314L (no) 2-arylimino-2,3-dihydrotiazoler og deres anvendelse som ligander for somatostatin-reseptorer
NO996115D0 (no) Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister
ID24726A (id) Antagonis-antagonis reseptor trombin
DK1027342T3 (da) Cyclopentenderivater som motilinreceptorantagonister
ID24162A (id) Antagonis-antagonis reseptor vitronektin
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
NO963331D0 (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO985970D0 (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
FI951798A0 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
NO992976D0 (no) Heterocykliske karboksylsyre-derivater, fremstilling og anvendelse derav som endothelinreseptor-antagonister
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
NO20022455D0 (no) Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander
NO20000324D0 (no) Benzotia (oksa) diazolderivater og deres anvendelse som endotelinreseptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application